CN110114079A - 一种预防和治疗肥胖症的方法和药物 - Google Patents

一种预防和治疗肥胖症的方法和药物 Download PDF

Info

Publication number
CN110114079A
CN110114079A CN201780078115.4A CN201780078115A CN110114079A CN 110114079 A CN110114079 A CN 110114079A CN 201780078115 A CN201780078115 A CN 201780078115A CN 110114079 A CN110114079 A CN 110114079A
Authority
CN
China
Prior art keywords
plasminogen
drug
obesity
subject
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780078115.4A
Other languages
English (en)
Inventor
李季男
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Talengen Institute of Life Sciences Co Ltd
Original Assignee
Talengen Institute of Life Sciences Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Talengen Institute of Life Sciences Co Ltd filed Critical Talengen Institute of Life Sciences Co Ltd
Publication of CN110114079A publication Critical patent/CN110114079A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

本发明涉及一种预防和/或治疗超重/肥胖及其相关病症的方法，包括给药易患或患有肥胖及其相关病症的受试者有效量的纤溶酶原，以消减脂肪在身体各部位的异常/过量沉积。本发明还涉及预防和/或治疗肥胖的药物，以及其在制备药物中的用途。

Description

PCT国内申请，说明书已公开。

Claims (48)

  1. PCT国内申请，权利要求书已公开。
CN201780078115.4A 2016-12-15 2017-12-15 一种预防和治疗肥胖症的方法和药物 Pending CN110114079A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2016/110172 2016-12-15
CN2016110172 2016-12-15
PCT/CN2017/116562 WO2018108161A1 (zh) 2016-12-15 2017-12-15 一种预防和治疗肥胖症的方法和药物

Publications (1)

Publication Number Publication Date
CN110114079A true CN110114079A (zh) 2019-08-09

Family

ID=62557993

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780078115.4A Pending CN110114079A (zh) 2016-12-15 2017-12-15 一种预防和治疗肥胖症的方法和药物

Country Status (7)

Country Link
US (1) US11207387B2 (zh)
EP (1) EP3556379A4 (zh)
JP (1) JP7168990B2 (zh)
CN (1) CN110114079A (zh)
CA (1) CA3047181A1 (zh)
TW (1) TW201829448A (zh)
WO (1) WO2018108161A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110366425A (zh) 2016-12-15 2019-10-22 泰伦基国际有限公司 一种预防动脉粥样硬化及其并发症的方法
EP3556389A4 (en) 2016-12-15 2020-07-15 Talengen International Limited METHOD FOR PREVENTING AND TREATING HEPATIC FIBROSIS
CA3047181A1 (en) 2016-12-15 2018-06-21 Talengen International Limited Method and drug for preventing and treating obesity
WO2018107707A1 (zh) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种改善心脏病变的方法
CN111344004A (zh) * 2017-06-19 2020-06-26 泰伦基国际有限公司 一种调控glp-1/glp-1r 的方法和药物
TW201904990A (zh) * 2017-06-23 2019-02-01 美商波麥堤克生物治療股份有限公司 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080200387A1 (en) * 2007-02-15 2008-08-21 Hua-Lin Wu Anti-angiogenic protein, composition and use thereof
US20090208448A1 (en) * 2008-02-15 2009-08-20 Solomon Keith R Inhibition of angiogenesis
CN102482338A (zh) * 2009-07-10 2012-05-30 斯路姆基因公司 纤溶酶原和纤溶酶的变体

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4245051A (en) 1978-03-30 1981-01-13 Rockefeller University Human serum plasminogen activator
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4658830A (en) 1984-08-08 1987-04-21 Survival Technology, Inc. Method and apparatus for initiating reperfusion treatment by an unattended individual undergoing heart attack symptoms
DE3515869A1 (de) 1985-05-03 1986-11-13 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung optisch aktiver azolderivate
JPS62153224A (ja) 1985-12-27 1987-07-08 Green Cross Corp:The プラスミノゲン製剤
GB8721951D0 (en) 1987-09-18 1987-10-28 Thrombosis Research Trust Organic compounds
JP2764264B2 (ja) 1987-10-01 1998-06-11 株式会社ミドリ十字 線溶活性増強剤
AU4661493A (en) 1992-07-01 1994-01-31 Beth Israel Hospital Boston Enhancement of thrombolytic therapy with deglycosylated plasminogen
US5520912A (en) 1993-07-02 1996-05-28 Immuno Aktiengesellschaft Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen
DK125693D0 (zh) 1993-11-05 1993-11-05 Novo Nordisk As
DE4411143C2 (de) 1994-03-30 1996-08-01 Immuno Ag Thrombosemittel
BR9609743A (pt) 1995-07-27 1999-03-02 Genentech Inc Formulação reconstituída estável método para a preparação de uma formulação artigo manufaturado e uso da formação
WO1999000420A1 (en) 1997-06-26 1999-01-07 Karolinska Innovations Ab Kringle domains 1-5 of plasminogen, capable of modulating angiogenesis in vivo
US7317003B2 (en) 1998-09-04 2008-01-08 National University Of Singapore Small peptides having anti-angiogenic and endothelial cell inhibition activity
US6465424B1 (en) 1999-02-17 2002-10-15 Bristol-Myers Squibb Company Anti-angiogenic agent and method for inhibiting angiogenesis
WO2000049871A1 (en) 1999-02-24 2000-08-31 Henry Ford Health System An anti-angiogenic kringle protein and its mutants
US6899877B2 (en) 1999-03-09 2005-05-31 Minu, L.L.C. Process for generating plasmin in the vitreous of the eye and inducing separation of the posterior hyaloid from the retina
US7544500B2 (en) 1999-11-13 2009-06-09 Talecris Biotherapeutics, Inc. Process for the production of a reversibly inactive acidified plasmin composition
US6964764B2 (en) 1999-11-13 2005-11-15 Talecris Biotherapeutics, Inc. Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
US20020159992A1 (en) 2000-09-29 2002-10-31 Jack Henkin Antiangiogenic polypeptides and methods for inhibiting angiogenesis
US20030054988A1 (en) 2000-11-02 2003-03-20 Weidong-Richard Ji Modified plasminogen related peptide fragments and their use as angiogenesis inhibitors
JP2005507244A (ja) 2001-08-10 2005-03-17 ノバルティス アクチエンゲゼルシャフト アテローム硬化性病変に結合するペプチド
US7067492B2 (en) 2001-09-06 2006-06-27 Omnio Ab Method of promoting healing of a tympanic membrane perforation
CN1408431A (zh) 2001-09-21 2003-04-09 北京华兴生生物技术有限公司 治疗与新生血管生成相关疾病的基因工程药物
US7202066B2 (en) 2002-01-29 2007-04-10 Carrington Laboratories, Inc. Combination of a growth factor and a protease enzyme
MXPA04007585A (es) 2002-02-06 2005-09-20 N Zyme Biotec Gmbh Metodo para la produccion de proteinas recombinantes en microorganismos.
DE10390418D2 (de) 2002-02-06 2005-01-13 N Zyme Biotec Gmbh Verfahren zur Herstellung von rekombinanten Proteinen in Mikroorganismen
US20030199464A1 (en) 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
BR0311172A (pt) 2002-05-13 2005-04-26 Children S Hospital Los Angele Tratamento e prevenção de formação de cicatriz anormal em quelóides e outras lesões ou ferimentos internos ou cutâneos
IL165253A0 (en) 2002-05-17 2005-12-18 Esperion Therapeutics Inc Methods and compositions for the treatment of ischemic reperfusion
CN100446772C (zh) 2002-12-06 2008-12-31 法布罗根股份有限公司 一种稳定HIFα的制剂在制备治疗糖尿病的药物中的应用
CA2509222A1 (en) 2002-12-10 2004-06-24 Wyeth Substituted indole oxo-acetyl amino acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
CN1451746A (zh) 2003-03-20 2003-10-29 广州市启源生物科技有限公司 人纤溶酶原Kringle 5缺失突变重组多肽
JPWO2005026127A1 (ja) 2003-09-11 2006-11-16 株式会社医薬分子設計研究所 プラスミノゲンアクチベータインヒビター−１阻害剤
US20080017694A1 (en) 2003-09-24 2008-01-24 Alexander Schnell Braze Alloy And The Use Of Said Braze Alloy
JP4740531B2 (ja) 2003-09-30 2011-08-03 雪印乳業株式会社 骨吸収抑制剤
MXPA06012236A (es) 2004-04-22 2007-01-31 Talecris Biotherapeutics Inc Plasmina modificada en forma recombinante.
US8357147B2 (en) * 2005-08-17 2013-01-22 Spinal Restoration, Inc. Method for repairing intervertebral discs
FR2882654B1 (fr) 2005-03-01 2007-04-27 Servier Lab Utilisation de derives de la diosmetine pour le traitement et la prevention des pathologies thrombotiques
WO2006095713A1 (ja) 2005-03-08 2006-09-14 Institute Of Medicinal Molecular Design. Inc. プラスミノゲンアクチベータインヒビター－１阻害剤
CA2602946A1 (en) 2005-03-22 2006-09-28 Medstar Health, Inc. Delivery systems and methods for diagnosing and treating cardiovascular diseases
US20060257391A1 (en) 2005-05-11 2006-11-16 Bausch & Lomb Incorporated Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions
EP2000145A4 (en) 2006-03-24 2010-08-25 Rohto Pharma AGENT FOR ENHANCING METABOLIC SYNDROME
WO2008026999A2 (en) 2006-08-28 2008-03-06 Omnio Healer Ab Candidates against infection
US20100028321A1 (en) 2006-08-28 2010-02-04 Omnio Healer Ab Drug target for preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health
EP2079476B1 (en) 2006-10-20 2014-05-21 Dow Global Technologies LLC Uses of hydroxypropyl methylcellulose for preventing or treating metabolic syndrome
CN101219219B (zh) 2007-01-10 2013-02-13 北京普罗吉生物科技发展有限公司 包含血管抑素或其片段的复合物、其制备方法及应用
CN101015686B (zh) 2007-02-06 2010-05-19 中国人民解放军军事医学科学院基础医学研究所 一种溶栓药物增效剂及其制备方法
AR067446A1 (es) 2007-07-11 2009-10-14 Otsuka Pharma Co Ltd Un medicamento para tratar higado graso que comprende cilostazol
EP2201946A4 (en) 2007-10-23 2012-01-25 Inst Med Molecular Design Inc HAMMER OF PAI-1 PRODUCTION
US20090239868A1 (en) 2007-10-23 2009-09-24 Institute Of Medical Molecular Design, Inc. Inhibitor of pai-1 production
AU2008331545B2 (en) 2007-11-29 2014-01-16 Grifols Therapeutics Inc. Recombinantly modified plasmin
WO2009089059A2 (en) 2008-01-09 2009-07-16 Intrexon Corporation Therapeutic inhibitors of pai-1 function methods of their use
EP2382467A1 (en) 2008-12-30 2011-11-02 IKFE GmbH Biomarkers for adipose tissue activity
US20120053222A1 (en) 2009-01-23 2012-03-01 Mark Gorrell Novel Metabolic Disease Therapy
BRPI1013392A2 (pt) 2009-03-31 2016-03-29 Renascience Co Ltd inibidor do inibidor-1 do ativador do plasminogênio
WO2010125148A2 (en) 2009-04-30 2010-11-04 Catherine Blondel Methods for treating ocular conditions
CN102647994A (zh) 2009-08-12 2012-08-22 康奈尔大学 预防或治疗代谢综合症的方法
CN101628113B (zh) 2009-08-18 2012-01-04 南京农业大学 蚯蚓纤溶酶抗肝纤维化的应用
CN101897925B (zh) 2009-12-16 2015-04-29 成都百康医药工业药理毒理研究院 一种治疗代谢综合症的药物组合物
US20120114652A1 (en) 2010-05-03 2012-05-10 Abbott Laboratories Anti-pai-1 antibodies and methods of use thereof
CN102121023B (zh) 2010-12-22 2012-07-04 中山大学 突变型人纤溶酶原kringle5及其制备方法及应用
MX337248B (es) 2011-01-05 2016-02-19 Thrombogenics Nv Variantes de plasminogeno y plasmina.
CN102154253A (zh) 2011-01-06 2011-08-17 郑州大学 具有抑制血小板凝集功能的微小纤溶酶原突变体及其制备方法和用途
CA2829051C (en) 2011-03-03 2020-04-28 Tersus Pharmaceuticals, LLC Compositions and methods comprising c16:1n7-palmitoleate
CN102199587B (zh) 2011-03-24 2013-06-19 广东药学院 人纤溶酶原功能性突变体及其制备方法和应用
JP2014510758A (ja) 2011-03-30 2014-05-01 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム ほ乳類において脂肪細胞を標的とするための方法および組成物
CN102188699A (zh) 2011-05-06 2011-09-21 南京农业大学 一种治疗动脉粥样硬化的药物组合物及其制备方法和应用
US20120058537A1 (en) 2011-07-27 2012-03-08 Fereidoun Mahboudi Chimeric truncated and mutant variant of tissue plasminogen activator (t-pa) resistant to plasminogen activator inhibitor-1
WO2013024074A1 (en) 2011-08-12 2013-02-21 Thrombogenics N.V. Plasminogen and plasmin variants
CN102532326B (zh) 2011-11-18 2017-06-09 南京大学 一种肿瘤靶向的人纤溶酶原Kringle5变体及其应用
CN103656630B (zh) 2012-09-11 2015-07-08 江苏仁寿药业有限公司 一种提纯动物药材中纤溶酶并制备成中药组合物的方法
CN105008323B (zh) 2012-10-31 2018-11-06 密歇根大学董事会 纤溶酶原激活物抑制因子-1抑制剂和其使用方法
US9134326B2 (en) 2013-03-14 2015-09-15 Battelle Memorial Institute Biomarkers for liver fibrosis
CN104274449A (zh) 2013-07-11 2015-01-14 无锡信达医疗器械有限公司 治疗肥胖症的药物组合物
CN112142845A (zh) 2013-08-13 2020-12-29 赛诺菲 纤溶酶原激活剂抑制剂-1(pai-1)的抗体及其用途
TW201722994A (zh) 2013-08-13 2017-07-01 賽諾菲公司 胞漿素原活化素抑制劑-１（ｐａｉ-１）之抗體及其用途
US20160199466A1 (en) 2013-08-20 2016-07-14 Trustees Of Dartmouth College Methods For Treating Tissue Fibrosis
TWI801331B (zh) 2015-11-03 2023-05-11 美商波麥堤克生物治療股份有限公司 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法
WO2017101867A1 (zh) 2015-12-18 2017-06-22 深圳瑞健生命科学研究院有限公司 一种预防或治疗糖尿病性神经损伤及其相关病症的方法
CN108778320A (zh) 2015-12-18 2018-11-09 泰伦基国际有限公司 一种预防和治疗心血管病的新方法
JP2019500422A (ja) 2015-12-18 2019-01-10 タレンゲン インターナショナル リミティッドＴａｌｅｎｇｅｎ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｌｉｍｉｔｅｄ 急性及び慢性血栓を予防または治療することに用いる方法
EP3395354B1 (en) 2015-12-18 2024-05-22 Talengen International Limited Plasminogen for use in treating diabetic nephropathy
WO2017101869A1 (zh) 2015-12-18 2017-06-22 深圳瑞健生命科学研究院有限公司 一种预防和治疗肝组织损伤及其相关病症的方法
CN110366425A (zh) 2016-12-15 2019-10-22 泰伦基国际有限公司 一种预防动脉粥样硬化及其并发症的方法
CA3047181A1 (en) 2016-12-15 2018-06-21 Talengen International Limited Method and drug for preventing and treating obesity
WO2018107707A1 (zh) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种改善心脏病变的方法
CN111344004A (zh) 2017-06-19 2020-06-26 泰伦基国际有限公司 一种调控glp-1/glp-1r 的方法和药物
TW201904990A (zh) 2017-06-23 2019-02-01 美商波麥堤克生物治療股份有限公司 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080200387A1 (en) * 2007-02-15 2008-08-21 Hua-Lin Wu Anti-angiogenic protein, composition and use thereof
US20090208448A1 (en) * 2008-02-15 2009-08-20 Solomon Keith R Inhibition of angiogenesis
CN102482338A (zh) * 2009-07-10 2012-05-30 斯路姆基因公司 纤溶酶原和纤溶酶的变体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
C.DANESE等: "Lipoprotein (a) and plasminogen in atherosclerosis", 《MINERVA CARDIOANGIOLOGICA》 *
QING XIAO等: "Plasminogen deficiency accelerates vessel wall disease in mice predisposed to atherosclerosis", 《PROC. NATL. ACAD. SCI.》 *

Also Published As

Publication number Publication date
US11207387B2 (en) 2021-12-28
CA3047181A1 (en) 2018-06-21
US20190328849A1 (en) 2019-10-31
JP2020502153A (ja) 2020-01-23
WO2018108161A1 (zh) 2018-06-21
EP3556379A1 (en) 2019-10-23
JP7168990B2 (ja) 2022-11-10
TW201829448A (zh) 2018-08-16
EP3556379A4 (en) 2020-08-19

Similar Documents

Publication Publication Date Title
CN110114079A (zh) 一种预防和治疗肥胖症的方法和药物
CN110167583A (zh) 一种治疗冠状动脉粥样硬化及其并发症的方法
TWI752044B (zh) 一種預防和治療組織器官纖維化的方法
CN108463240A (zh) 一种预防或治疗糖尿病性视网膜病变的方法
CN110114081A (zh) 一种改善心脏病变的方法
CN108210906A (zh) 治疗冠状动脉粥样硬化及其并发症的药物及其用途
CN110402150A (zh) 一种预防和治疗骨质疏松的药物及其用途
TWI746581B (zh) 纖溶酶原在製備預防和治療脂質腎損傷之藥劑上的用途
CN108463236A (zh) 一种预防或治疗放射性和化学性损伤的方法
TW202123962A (zh) 一種預防和治療腎纖維化的方法
CN108210917A (zh) 一种预防和治疗肥胖症的方法和药物
CN106890324A (zh) 一种预防和治疗糖尿病肾病的方法
CN108210909A (zh) 预防和治疗脂质肾损伤的药物及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination